Skip to main content

Market Overview

Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing Pact

Share:
Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing Pact
  • Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and privately-held OyaGen Inc have entered into an exclusive worldwide licensing agreement for TNX-3500 (sangivamycin, formerly OYA1) for the treatment of COVID-19 and potentially other viral disorders.
  • Under the terms of the agreement, Tonix will conduct further studies to test the safety and efficacy of TNX-3500 in treating COVID-19.
  • The financial details of the deal were not disclosed.
  • TNX-3500 (sangivamycin) has demonstrated broad-spectrum antiviral activity in laboratory-based assays against the coronaviruses SARS-CoV-2 and MERS-CoV. Sangivamycin also demonstrated that it acts as a dual target-specific antiviral against filoviruses such as the Ebola virus in cell culture infectivity studies.
  • Tonix is also developing a COVID-19 vaccine, TNX-1800, which is currently in preclinical studies.
  • Last month, the company reported interim data demonstrating that all eight of the TNX-1800 vaccinated animals made anti-CoV-2 neutralizing antibodies against none in the control arm and placebo group after a single dose.
  • The human study will start in the second half of this year.
  • Also, Tonix announced its plans to develop a diagnostic skin test, TNX-2100, to measure the delayed-type hypersensitivity reaction to SARS-CoV-2.
  • Price Action: TNXP shares are up 9.2% at $1.07 in the premarket trading session on the last check Monday.
 

Related Articles (TNXP)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Penny Stocks Health Care Contracts Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com